Objective: To describe characteristics of the immunogenicity of SARS-CoV-2 neutralizing antibody (anti-RBD antibody) among healthcare providers vaccinated with at least one dose of ChAdOx1 nCoV-19 AZD1222 (Oxford-AstraZeneca, England).